CN Patent

CN110229103A — 一种乐伐替尼甲磺酸盐晶型b的制备方法

Assigned to SYNCORE LABORATORIES (SHANGHAI) Co Ltd · Expires 2019-09-13 · 7y expired

What this patent protects

本发明涉及乐伐替尼甲磺酸盐晶型B的制备方法，将4‑(3‑氯‑4‑(环丙基氨基羰基)氨基苯氧基)‑7‑甲氧基‑6‑喹啉羧酰胺和甲磺酸在特定有机溶剂中反应成盐，降温搅拌得到晶型B。本发明公开的制备晶型B的方法，工艺提纯效果显著，制备方法简单，工艺重现性好，对未来该药物晶型的优化和商业开发具有重要价值。

USPTO Abstract

本发明涉及乐伐替尼甲磺酸盐晶型B的制备方法，将4‑(3‑氯‑4‑(环丙基氨基羰基)氨基苯氧基)‑7‑甲氧基‑6‑喹啉羧酰胺和甲磺酸在特定有机溶剂中反应成盐，降温搅拌得到晶型B。本发明公开的制备晶型B的方法，工艺提纯效果显著，制备方法简单，工艺重现性好，对未来该药物晶型的优化和商业开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN110229103A
Jurisdiction
CN
Classification
—
Expires
2019-09-13
Drug substance claim
No
Drug product claim
No
Assignee
SYNCORE LABORATORIES (SHANGHAI) Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.